Surf Bio commercializes a polymer-based drug stabilization platform designed to formulate biologics at higher concentrations and in more thermostable forms than current technologies. The platform aims to eliminate refrigeration requirements and enable subcutaneous administration of biologics, improving accessibility in low- and middle-income countries. Surf Bio plans to apply the technology across oncology, autoimmune diseases, infectious diseases, gene therapy, and other therapeutic areas. In-vitro and in-vivo safety and efficacy data have demonstrated the platform may enable temperature-stable formulations, very high-concentration subcutaneous formulations, and novel therapeutic formulations. The company has ongoing collaborations with leading multinational pharmaceutical companies to explore using the polymer technology within their proprietary pipelines. Surf Bio was launched by the founders of Bigfoot Biomedical and Mode AGC to commercialize technology developed in the Appel lab at Stanford University. Surf Bio is a preclinical biopharmaceutical company developing a polymer-based drug stabilization and delivery platform to enhance the stability of biologics such as peptides, vaccines, and monoclonal antibodies. The platform is intended to enable higher-concentration and higher-temperature formulations, reduce refrigeration dependence, and allow transitions from IV to subcutaneous delivery. Surf Bio's lead program is an ultra-rapid insulin for diabetes; the company will use new funding to accelerate development of that program and its broader platform pipeline. The company reports demonstrated in‑vitro and in‑vivo safety and efficacy data and has multiple, ongoing collaborations with multinational pharmaceutical companies. Surf Bio was launched by the founders of Bigfoot Biomedical and Mode AGC to commercialize technology developed in the Appel Lab and is led by co-founder and CEO Bryan Mazlish. The company is based in Palo Alto, California and is currently in preclinical development.

Total raised

$18M

Funding rounds

2

Latest round

Grant

Latest activity

Apr 2024